Low-dose factor VIII infusion in Chinese adult haemophilia A patients: pharmacokinetics evidence that daily infusion results in higher trough level than with every-other-day infusion with similar factor VIII consumption

Haemophilia ◽  
2017 ◽  
Vol 23 (3) ◽  
pp. 417-421 ◽  
Author(s):  
B. Hua ◽  
A. Lee ◽  
L. Fan ◽  
K. Li ◽  
Y. Zhang ◽  
...  
Keyword(s):  
Factor Viii ◽  
Low Dose ◽  
Trough Level ◽  
Haemophilia A ◽  
Chinese Adult ◽  
Similar Factor ◽  
Dose Factor

Effect of low‐dose factor VIII prophylaxis therapy on bone mineral density and 25(OH) vitamin D level in children with severe haemophilia A

Haemophilia ◽  
2020 ◽  
Vol 26 (2) ◽  
pp. 325-332 ◽  
Author(s):  
Nevine Gamal Andrawes ◽  
Manal Hashem Fayek ◽  
Nouran Salah El‐Din ◽  
Raguia Atef Mostafa
Keyword(s):  
Bone Mineral Density ◽  
Vitamin D ◽  
Factor Viii ◽  
Low Dose ◽  
Haemophilia A ◽  
Severe Haemophilia ◽  
Mineral Density ◽  
Prophylaxis Therapy ◽  
25 Oh Vitamin D ◽  
Dose Factor

Model‐based evaluation of low‐dose factor VIII prophylaxis in haemophilia A

Haemophilia ◽  
2019 ◽  
Vol 25 (3) ◽  
pp. 408-415 ◽  
Author(s):  
Ari Brekkan ◽  
Johanna Degerman ◽  
Siv Jönsson
Keyword(s):  
Factor Viii ◽  
Low Dose ◽  
Haemophilia A ◽  
Model Based ◽  
Dose Factor

A randomized study of very low-dose factor VIII prophylaxis in severe haemophilia - A success story from a resource limited country

Haemophilia ◽  
2016 ◽  
Vol 22 (3) ◽  
pp. 342-348 ◽  
Author(s):  
S. P. Verma ◽  
T. K. Dutta ◽  
S. Mahadevan ◽  
P. Nalini ◽  
D. Basu ◽  
...  
Keyword(s):  
Factor Viii ◽  
Low Dose ◽  
Randomized Study ◽  
Haemophilia A ◽  
Severe Haemophilia ◽  
Success Story ◽  
Resource Limited ◽  
Dose Factor

Comparison of the efficacy and safety of 12‐month low‐dose factor VIII tertiary prophylaxis vs on‐demand treatment in severe haemophilia A children

Haemophilia ◽  
2019 ◽  
Author(s):  
Novie A. Chozie ◽  
Fitri Primacakti ◽  
Djajadiman Gatot ◽  
Rahajuningsih D. Setiabudhy ◽  
Angela B. M. Tulaar ◽  
...  
Keyword(s):  
Factor Viii ◽  
Low Dose ◽  
Haemophilia A ◽  
Severe Haemophilia ◽  
Efficacy And Safety ◽  
On Demand ◽  
Dose Factor

scholarly journals Effect of tertiary prophylaxis with low-dose factor VIII in quality of life in adult patients with severe hemophilia A

2019 ◽  
Vol 10 (3) ◽  
pp. 88
Author(s):  
PrakasKumar Mandal ◽  
Abhijit Phukan ◽  
Amrita Bhowmik ◽  
Debasis Gantait ◽  
Prantar Chakrabarti
Keyword(s):  
Quality Of Life ◽  
Factor Viii ◽  
Low Dose ◽  
Hemophilia A ◽  
Adult Patients ◽  
Severe Hemophilia ◽  
Dose Factor

Cross-evaluation of Pharmacokinetic-Guided Dosing Tools for Factor VIII

2018 ◽  
Vol 118 (03) ◽  
pp. 514-525 ◽  
Author(s):  
T. Preijers ◽  
I. van Moort ◽  
K. Fijnvandraat ◽  
F. Leebeek ◽  
M. Cnossen ◽  
...  
Keyword(s):  
Factor Viii ◽  
Half Life ◽  
Trough Level ◽  
Patient Characteristics ◽  
Population Pharmacokinetic ◽  
Parameter Estimates ◽  
Haemophilia A ◽  
Blood Samples ◽  
Fviii Activity ◽  
Recombinant Fviii

Background Patients with severe and moderate haemophilia A are treated prophylactically with factor VIII (FVIII) concentrate. Individualization of prophylaxis can be achieved by pharmacokinetic (PK)-guided dosing. Aim In this study, the performance of three PK tools (myPKFiT, Web-Accessible Population Pharmacokinetic Service-Hemophilia [WAPPS] and NONMEM) is compared. Methods In 39 patients, with severe or moderate haemophilia A, blood samples were collected 4, 24 and 48 hours after administration of 50 IU kg−1 of recombinant FVIII (Advate [n = 30] or Kogenate [n = 9]). FVIII dose, FVIII activity and patient characteristics were entered into the three PK tools. Obtained PK parameters and dosing advises were compared. Results myPKFiT provided PK parameters for 24 of 30 patients receiving Advate, whereas WAPPS and NONMEM provided estimates for all patients. Half-life was different among the three methods: medians were 12.6 hours (n = 24), 11.2 hours (n = 30) and 13.0 hours (n = 30) for myPKFiT, WAPPS and NONMEM (p < 0.001), respectively. To maintain a FVIII trough level of 0.01 IU mL−1 after 48 hours, doses for myPKFiT and NONMEM were 15.1 and 11.0 IU kg−1 (p < 0.01, n = 11) and for WAPPS and NONMEM were 9.0 and 8.0 IU kg−1 (p < 0.01, n = 23), respectively. In nine patients receiving Kogenate, WAPPS and NONMEM produced different PK-parameter estimates; half-life was 15.0 and 12.3 hours and time to 0.05 IU mL−1 was 69.2 and 60.8 hours, respectively (p < 0.01, n = 9). However, recommended doses to obtain these levels were not different. Conclusion The three evaluated PK tools produced different PK parameters and doses for recombinant FVIII. Haematologists should be aware that recommended doses may be influenced by the choice of PK tool.

Low-dose immune tolerance induction in hemophilia A patients with inhibitors

Blood ◽  
1995 ◽  
Vol 86 (3) ◽  
pp. 983-988 ◽  
Author(s):  
EP Mauser-Bunschoten ◽  
HK Nieuwenhuis ◽  
G Roosendaal ◽  
HM van den Berg
Keyword(s):  
Factor Viii ◽  
Immune Tolerance ◽  
Low Dose ◽  
Hemophilia A ◽  
Tolerance Induction ◽  
Immune Tolerance Induction ◽  
Inhibitor Development ◽  
Two Factors ◽  
Inhibitor Level ◽  
Dose Factor

Abstract In patients with hemophilia A and inhibitory alloantibodies against factor VIII, various dosage schedules are used to obtain immune tolerance. In this study, we have evaluated the results of 13 years of low-dose immune tolerance induction and factors that are predictive of a positive result. The effect of immune tolerance induction in relation to age at inhibitor development, number of exposure days, age at start of therapy, maximum inhibitor titer, factor VIII products involved, and virologic status were determined. We evaluated 24 patients with severe hemophilia A and inhibitors who were treated with regular infusions with low-dose (25 U/kg every other day) factor VIII to obtain immune tolerance. In 21 of 24 patients (87%), immune tolerance induction was successful. The response time was determined by two factors: the highest inhibitor level and the age at inhibitor development. In patients with maximum inhibitor levels of less than 40 Bethesda units (BU)/mL, immune tolerance was obtained sooner than in patients with inhibitor levels exceeding 40 BU/mL (P = .005). Patients in whom an inhibitor developed before the age of 2.5 years also tended to have a quick immune response (P = .014). Immune tolerance with low-dose factor VIII is often successful in hemophilia A patients with inhibitors. Young children and patients with maximum inhibitors of less than 40 BU/mL show a relatively rapid response.

Sign in / Sign up

Export Citation Format

Share Document